Table 1.
Synthesis of HIV prevention publications (n=9) included in our review (2012–2019)
Citation | Product of Interest | Sample size | Location | Attributes explored | Methodology |
---|---|---|---|---|---|
Eisingerich et al. (2012) | Diverse PrEP methods | N=1790 | Peru, Ukraine, India, Kenya, Botswana, Uganda & South Africa | Route of administration, Dispensing site, Time spent obtaining PrEP, frequency of pickup, and frequency of HIV testing associated with PrEP | Conjoint Analysis |
Kinsler et al. (2012) | Rectal microbicides | N=128 | Peru & Brazil | Cost, formulation, Prescription, Frequency of use, Effectiveness, side effectiveness, dosage/volume | Conjoint Analysis |
Cameron et al. (2013) | HIV Vaccine | N=326 | Thailand | Efficacy, Side effects, Duration of protection, Vaccine-Induced Seropositivity, Private vs Public Hospital, Proportion of population already vaccinated, and cost | Discrete Choice Experiment |
Wheelock et al. (2013) | Diverse PrEP methods | N=260 | Thailand | Route of administration, Dispensing site, Time spent obtaining PrEP, frequency of pickup, and frequency of HIV testing associated with PrEP | Conjoint Analysis |
Newman et al. (2016) | Rectal microbicides | N=143 | USA | Efficacy, duration of protection, cross-clade protection, doses, route, side effects, and cost | Discrete Choice Experiment |
Tang et al. (2016) | Rectal microbicides | N=1008 | Peru | Effectiveness, Frequency of use, Side effects, Costs, Prescription needed, Applicator Reusability | Conjoint Analysis |
Dubov et al. (2018) | Diverse PrEP methods | N=1184 | Ukraine | Dosing frequency, dispensing venue, prescription, adherence support, and cost | Conjoint Analysis |
Shrestha et al. (2018) | Diverse PrEP methods | N=400 | USA | Cost, dosing, efficacy, side effects, treatment setting, and frequency of HIV testing | Conjoint Analysis |
Dubov et al. (2019) | Diverse PrEP methods | N=554 | US | Dosing frequency, dispensing venue, prescription, adherence support, and cost | Discrete Choice Experiment |